US EditionPublished • loading... • Updated
How Novartis' Alzheimer’s Antibody Deal And US Radioligand Expansion At Novartis (SWX:NOVN) Has Changed Its Investment Story
Summary by Simply Wall St
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
How Novartis' Alzheimer’s Antibody Deal And US Radioligand Expansion At Novartis (SWX:NOVN) Has Changed Its Investment Story
In recent days, Novartis and SciNeuro Pharmaceuticals announced a worldwide licensing and collaboration deal to develop an amyloid beta antibody program for Alzheimer’s disease, while Novartis also unveiled plans for a new radioligand therapy manufacturing facility in Winter Park, Florida, as part of its multi-billion-dollar US investment. Together, these moves highlight how Novartis is pairing early-stage neuroscience innovation with expanded …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
